The company presented new data from its Alzheimer’s disease research efforts across its diagnostics and pharmaceutical ...

Swiss drugmaker Roche Holding plans to investigate whether an experimental medicine can delay or prevent Alzheimer’s disease ...

Sarepta’s Elevidys is back on the market for ambulatory patients with Duchenne muscular dystrophy, Health Secretary Robert F.

A new drug cleared 91% of brain amyloid plaques in 7 months, showing faster results than current Alzheimer's treatments and advancing to Phase III trials in 2025.

A breakthrough new drug could halt the progression of Alzheimer's disease, claim researchers. Trials suggest the drug—called ...

Cognition Therapeutics’ dementia drug showed up to a 129% slowing of cognitive decline in mild Alzheimer’s disease patients ...

See the latest Roche Holding AG ADR stock price (RHHBY:PINX), related news, valuation, dividends and more to help you make your investing decisions.

Roche's anti-TIGIT antibody tiragolumab has failed a second phase 3 trial, dousing expectations for the programme and its hopes of finding a companion to its cancer immunotherapy blockbuster ...

Roche has revealed good results from a phase 2 trial of its oral BTK drug fenebrutinib in relapsing multiple sclerosis as it waits for phase 3 data.